PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
45.56%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
30.89%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
30.77%
EPS growth at 75-90% of GNPX's 34.62%. Bill Ackman would push for improved profitability or share repurchases to catch up.
30.77%
Diluted EPS growth at 75-90% of GNPX's 34.62%. Bill Ackman would expect further improvements in net income or share count reduction.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
OCF growth above 1.5x GNPX's 7.14%. David Dodd would confirm a clear edge in underlying cash generation.
98.49%
FCF growth above 1.5x GNPX's 7.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
10Y OCF/share CAGR in line with GNPX's 91.62%. Walter Schloss would see both as similarly efficient over the decade.
94.54%
5Y OCF/share CAGR is similar to GNPX's 96.48%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
94.54%
3Y OCF/share CAGR similar to GNPX's 96.26%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-8.80%
Negative 10Y net income/share CAGR while GNPX is at 99.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-8.80%
Negative 5Y net income/share CAGR while GNPX is 96.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-8.80%
Negative 3Y CAGR while GNPX is 96.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-273.39%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-273.39%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-273.39%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.63%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.22%
Debt growth of 0.22% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
We cut SG&A while GNPX invests at 52.68%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.